| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02014129 | Neoplasm Metastasis|Lymphoma | Drug: LY2835219 | Eli Lilly and Company | Phase 1 | 2013-12-01 | 2017-02-14 |
| NCT02327143 | Healthy Volunteers | Drug: LY2835219|Drug: ^13C-LY2835219 | Eli Lilly and Company | Phase 1 | 2015-01-01 | 2015-02-24 |
| NCT02059148 | Healthy Volunteers | Drug: LY2835219 | Eli Lilly and Company | Phase 1 | 2014-02-01 | 2014-11-19 |
| NCT02117648 | Neoplasm|Neoplasm Metastasis | Drug: LY2835219|Drug: Clarithromycin | Eli Lilly and Company | Phase 1 | 2014-04-01 | 2015-09-17 |
| NCT01913314 | Healthy Volunteers | Drug: [^14C]-LY2835219 | Eli Lilly and Company | Phase 1 | 2013-08-01 | 2014-11-19 |
| NCT02256267 | Healthy Volunteers | Drug: LY2835219|Drug: Rifampin | Eli Lilly and Company | Phase 1 | 2014-10-01 | 2014-12-17 |
| NCT01739309 | Mantle Cell Lymphoma | Drug: LY2835219 | Eli Lilly and Company | Phase 2 | 2013-03-01 | 2017-03-08 |
| NCT01394016 | Advanced Cancer | Drug: LY2835219|Drug: Fulvestrant | Eli Lilly and Company | Phase 1 | 2009-12-07 | 2017-03-20 |
| NCT02102490 | Metastatic Breast Cancer | Drug: Abemaciclib | Eli Lilly and Company | Phase 2 | 2014-06-01 | 2016-08-13 |
| NCT02450539 | Non-Small Cell Lung Cancer Stage IV | Drug: Abemaciclib|Drug: Docetaxel | Eli Lilly and Company | Phase 2 | 2015-08-01 | 2017-03-06 |
| NCT02246621 | Breast Cancer | Drug: Abemaciclib|Drug: Anastrozole|Drug: Letrozole|Drug: Placebo | Eli Lilly and Company | Phase 3 | 2014-11-01 | 2017-01-09 |
| NCT02441946 | Breast Cancer|Hormone Receptor Positive Tumor|Early-Stage Breast Carcinoma | Drug: Abemaciclib|Drug: Loperamide|Drug: Anastrozole | Eli Lilly and Company | Phase 2 | 2015-08-01 | 2017-01-24 |
| NCT02846987 | Sarcoma|Dedifferentiated Liposarcoma | Drug: Abemaciclib | Memorial Sloan Kettering Cancer Center|Eli Lilly and Company | Phase 2 | 2016-07-01 | 2016-12-22 |
| NCT02079636 | Carcinoma, Non-small Cell Lung | Drug: Abemaciclib|Drug: Pemetrexed|Drug: Gemcitabine|Drug: Ramucirumab|Drug: LY3023414|Drug: Pembrolizumab | Eli Lilly and Company|Merck Sharp & Dohme Corp. | Phase 1 | 2014-03-01 | 2017-03-21 |
| NCT02057133 | Breast Neoplasms | Drug: LY2835219|Drug: Letrozole|Drug: Anastrozole|Drug: Tamoxifen|Drug: Exemestane|Drug: Everolimus|Drug: Trastuzumab|Drug: LY3023414|Drug: Fulvestrant | Eli Lilly and Company | Phase 1 | 2014-03-01 | 2017-03-17 |
| NCT02763566 | Breast Cancer | Drug: Abemaciclib|Drug: Anastrozole|Drug: Letrozole|Drug: Placebo|Drug: Fulvestrant | Eli Lilly and Company | Phase 3 | 2016-12-01 | 2017-03-22 |
| NCT02482935 | Healthy | Drug: Abemaciclib | Eli Lilly and Company | Phase 1 | 2015-06-01 | 2015-10-16 |
| NCT02779751 | Non Small Cell Lung Cancer|Breast Cancer | Drug: Abemaciclib|Drug: Pembrolizumab | Eli Lilly and Company|Merck Sharp & Dohme Corp. | Phase 1 | 2016-11-14 | 2017-03-21 |
| NCT02152631 | Non Small Cell Lung Cancer | Drug: Abemaciclib|Drug: Erlotinib | Eli Lilly and Company | Phase 3 | 2014-09-01 | 2017-03-06 |
| NCT02675231 | Hormone Receptor Positive Tumor|HER-2 Positive Breast Cancer | Drug: Abemaciclib|Drug: Trastuzumab|Drug: Fulvestrant|Drug: Standard of Care Single Agent Chemotherapy | Eli Lilly and Company | Phase 2 | 2016-03-01 | 2017-03-22 |
| NCT02919696 | Advanced Cancer|Metastatic Cancer | Drug: Abemaciclib | Eli Lilly and Company | Phase 1 | 2017-04-17 | 2017-02-24 |
| NCT02747004 | Metastatic Breast Cancer | Drug: Abemaciclib|Drug: Tamoxifen|Drug: Prophylactic Loperamide | Eli Lilly and Company | Phase 2 | 2016-09-01 | 2017-03-21 |
| NCT02792725 | Metastatic Breast Cancer | Drug: Abemaciclib | Eli Lilly and Company | | null | 2017-03-23 |
| NCT02107703 | Breast Neoplasms | Drug: Abemaciclib|Drug: Fulvestrant|Drug: Placebo | Eli Lilly and Company | Phase 3 | 2014-07-01 | 2017-03-02 |
| NCT02308020 | Breast Cancer|Non-small Cell Lung Cancer|Melanoma|Brain Metastases | Drug: Abemaciclib | Eli Lilly and Company | Phase 2 | 2015-04-01 | 2017-03-03 |
| NCT02387814 | Hepatic Insufficiency|Healthy | Drug: Abemaciclib | Eli Lilly and Company | Phase 1 | 2015-03-01 | 2015-09-10 |
